✦ LIBER ✦

Treatment of type 1 diabetes with anti-CD3 monoclonal antibody

✍ Scribed by Kaven C. Herold; Lesley Taylor

Book ID: 111639207
Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 113 KB
Volume: 28
Category: Article
ISSN: 0257-277X
DOI: 10.1385/ir:28:2:141

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Type 1 Diabetes with Anti-C

Treatment of Type 1 Diabetes with Anti-CD3 Monoclonal Antibody

✍ Mariela Glandt; William Hagopian; Kevan C. Herold 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 101 KB

Anti-CD3 Monoclonal Antibody in New-Onse

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

✍ Herold, Kevan C.; Hagopian, William; Auger, Julie A.; Poumian-Ruiz, Ena; Taylor, 📂 Article 📅 2002 🏛 Massachusetts Medical Society 🌐 English ⚖ 110 KB

Anti-CD3 monoclonal antibody treatment i

Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis

✍ J. Smith-Palmer; B. H. Curtis; K. S. Boye; G. Goodall; S. R. Pillemer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

Use of Anti-CD3 Monoclonal Antibody to I

Use of Anti-CD3 Monoclonal Antibody to Induce Immune Regulation in Type 1 Diabetes

✍ BRYGIDA C. BISIKIRSKA; KEVAN C. HEROLD 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 799 KB

Treatment of posttransplantation diabete

Treatment of posttransplantation diabetes mellitus with anti-CD20 monoclonal antibodies

✍ K. Vandenbosch; M.A. Champagne; M. Gonthier; A. Moghrabi; M.-F. Vachon; M. Duval 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Anti-CD3 mAbs for treatment of type 1 di

Anti-CD3 mAbs for treatment of type 1 diabetes

✍ Adam Kaufman; Kevan C. Herold 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

## Abstract The use of anti‐CD3 monoclonal antibodies (mAbs) has moved from the bench to the bedside. The experience with the anti‐human CD3 mAb OKT3 for treatment of transplant rejection identified limitations that were largely overcome with the creation of humanized non‐FcR binding antibodies: Te